Digestive Disease Week® 2018 Media Briefing Previewing the Latest Research & Hot Topics

Digestive Disease Week® 2018 Media Briefing Previewing the Latest Research & Hot Topics

WHAT: A webinar media briefing with researchers to preview studies being presented at DDW® 2018 in Washington, DC


  • Michael B. Wallace, MD, MPH, professor of medicine and a primary investigator on the Phase III Trial
  • Francisco Leon, MD, PhD, former CEO/CMO of Celimmune, currently a consultant for Amgen Inc.
  • Toan Pham, a PhD candidate and research fellow at the Peter MacCallum Cancer Centre at the University of Melbourne, Australia
  • Saroja Bangaru, MD, chief resident in internal medicine at University of Texas Southwestern Medical Center, Dallas

WHEN: Monday, May 21; 10 – 11 a.m. EDT

RSVP: Register now. If you have any problems accessing the registration link, please copy and paste the following URL into your browser: https://attendee.gotowebinar.com/register/405203410791232258

Members of the media interested in receiving the embargoed news releases should contact Stephanie Wight, [email protected], (202) 868-4016. News releases presented during the telebriefing are embargoed until 12:01 a.m. EDT on Tuesday, May 22. Other data presented at DDW is embargoed for the beginning of its presentation time. View the DDW online plannerto access presentation times.

 Embargoed News Releases Available Upon Request

Selected studies include:

Methylene Blue MMX increases adenoma detection rate in screening and surveillance colonoscopy: a multi-centre, multinational, placebo controlled, randomised, double-blind at randomization, parallel-group, phase 3 study

Michael B. Wallace, MD, MPH, abstract 395

Every year, nearly 137,000 people are diagnosed with colorectal cancer (CRC), and more than 50,000 people die from it. One of the biggest barriers to prevention of CRC is inadequate detection of polyps during screening. A new study finds that ingestion of a blue dye tablet during bowel prep for colonoscopy increased adenoma detection rate significantly.

AMG 714 (ANTI-IL-15 MAB) ameliorates the effects of gluten consumption in celiac disease: A phase 2a, randomized, double-blind, placebo-controlled study evaluating AMG 714 in adult patients with celiac disease exposed to high-dose gluten challenge

Francisco Leon, MD, abstract 618

Celiac disease, a serious autoimmune disorder that can cause intestinal damage, is estimated to affect one in 100 people worldwide. An investigational new drug, AMG 714, offers hope for celiac disease patients who are inadvertently exposed to gluten while on a gluten-free diet by reducing activation of the immune system, leading to fewer symptoms following gluten exposure.

 Cancer vaccine targeting MYB in colorectal cancer: From pre-clinical model to clinical trial

Toan Pham, abstract 421

Colorectal cancer (CRC) is the third most common cancer diagnosed in both men and women in the U.S. Researchers will be testing, for the first time in humans, a two-pronged approach to treat advanced-stage CRC with the potential to increase life expectancy. By combining a DNA vaccine that boosts the body’s immune response against tumors with an antibody that blocks the body’s natural defense against the potency of such immunotherapy, researchers are hoping to develop an effective treatment for late stage disease, when a cure is not often possible.

Increased use of liver transplantation as therapeutic option for severe alcoholic hepatitis

Saroja Bangaru, MD, abstract Sa1457

Alcoholic hepatitis is an inflammation of the liver caused by excessive drinking of alcohol, with the more severe cases having extremely high mortality and very limited treatment options. According to a new survey, an increasing number of liver transplant centers are successfully reversing a long-standing practice of delaying potentially life-saving transplants for patients until after they stopped drinking alcohol for six months.


Digestive Disease Week® (DDW) is the largest international gathering of physicians, researchers and academics in the fields of gastroenterology, hepatology, endoscopy and gastrointestinal surgery. Jointly sponsored by the American Association for the Study of Liver Diseases (AASLD), the American Gastroenterological Association (AGA) Institute, the American Society for Gastrointestinal Endoscopy (ASGE) and the Society for Surgery of the Alimentary Tract (SSAT), DDW takes place June 2-5, at Walter E. Washington Convention Center, DC. The meeting showcases more than 5,000 abstracts and hundreds of lectures on the latest advances in GI research, medicine and technology. More information can be found at www.ddw.org.

Follow us on Twitter @DDWMeeting; hashtag #DDW18. Become a fan of DDW on Facebook.